Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis

Autor:	Xiao-Lin Wang, Bao Li, Shu-Ling Rong, Zhi-Ming Yang, Z. Wang, Xuedong Zhou
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Cardiomyopathy Dilated Male Risk 0301 basic medicine medicine.medical_specialty Systole medicine.medical_treatment Dilated cardiomyopathy lcsh:Medicine Walk Test Cochrane Library General Biochemistry Genetics and Molecular Biology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Diastole law Internal medicine medicine Humans Clinical significance Systematic appraisal Stem cell therapy Ejection fraction business.industry Research lcsh:R Stroke Volume General Medicine Stem-cell therapy Middle Aged medicine.disease Meta-analysis Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Relative risk Cardiology Female business Publication Bias Stem Cell Transplantation
Zdroj:	Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-14 (2019) Journal of Translational Medicine
ISSN:	1479-5876
DOI:	10.1186/s12967-019-1966-4
Popis:	Background The clinical significance of stem cell therapy in the treatment of dilated cardiomyopathy remains unclear. This systemic appraisal and meta-analysis aimed to assess the efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy. After searching the PubMed, Embase, and Cochrane library databases until November 2017, we conducted a meta-analysis to evaluate the efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy. Methods The weighted mean difference (WMD), standard mean difference (SMD), relative risk (RR), and 95% confidence interval (CI) were summarized in this meta-analysis. Both fixed effects and random effects models were used to combine the data. Sensitivity analyses were conducted to evaluate the impact of an individual dataset on the pooled results. Results A total of eight randomized controlled trials, which involved 531 participants, met the inclusion criteria in this systematic appraisal and meta-analysis. Our meta-analysis showed that stem cell therapy improves left ventricular ejection fraction (SMD = 1.09, 95% CI 0.29 to 1.90, I 2 = 92%) and reduces left ventricular end-systolic volume (SMD = − 0.36, 95% CI − 0.61 to − 0.10, I 2 = 20.5%) and left ventricular end-diastolic chamber size (SMD = − 0.48, 95% CI − 0.89 to − 0.07, I 2 = 64.8%) in patients with dilated cardiomyopathy. However, stem cell therapy has no effect on mortality (RR = 0.72, 95% CI 0.50 to 1.02, I 2 = 30.2%) and 6-min-walk test (WMD = 51.52, 95% CI − 24.52 to 127.55, I 2 = 94.8%). Conclusions This meta-analysis suggests that stem cell therapy improves left ventricular ejection fraction and reduces left ventricular end-systolic volume and left ventricular end-diastolic chamber size in patients with dilated cardiomyopathy. However, future well-designed large studies might be necessary to clarify the effect of stem cell therapy in patients with dilated cardiomyopathy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e7e527fa2b4245d730f1ccac1adf85 http://link.springer.com/article/10.1186/s12967-019-1966-4 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.